zyvox
laboratÓrios pfizer ltda - antibioticos sistemicos simples
jakavi
novartis europharm limited - ruxolitinib (como fosfato) - myeloproliferative disorders; polycythemia vera; graft vs host disease - agentes antineoplásicos - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi é indicado para o tratamento de pacientes adultos com polycythaemia vera que são resistentes ou intolerantes hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.
abilify
bristol-myers squibb farmacÊutica ltda - antipsicoticos
aripiprazol
achÉ laboratÓrios farmacÊuticos s.a - aripiprazol - antipsicoticos
aripiprazol
sandoz do brasil indÚstria farmacÊutica ltda - aripiprazol - antipsicoticos
aripiprazol
unichem farmacÊutica do brasil ltda - aripiprazol - antipsicoticos
aripiprazol
zydus nikkho farmacÊutica ltda - aripiprazol - antipsicoticos
aristab
achÉ laboratÓrios farmacÊuticos s.a - aripiprazol - antipsicoticos
asmafin
cazi quimica farmaceutica industria e comercio ltda - aminofilina - broncodilatadores
confilify
sandoz do brasil indÚstria farmacÊutica ltda - aripiprazol - antipsicoticos